Neuromielitis óptica y enfermedad anti-MOG

  1. Alberte Woodward, M. 1
  2. García de Soto, J. 1
  3. Prieto González, J.M.Ó 1
  1. 1 Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2023

Título do exemplar: Enfermedades del sistema nervioso (IX): Enfermedades desmielinizantes

Serie: 13

Número: 78

Páxinas: 4635-4640

Tipo: Artigo

DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

The classic term neuromyelitis optica (NMO) has been replaced by NMO spectrum disorder (NMOSD) as a result of the identification of the diagnostic marker of the disease (IgG-AQP4) and the inclusion of features such as area postrema syndrome or diencephalic disturbances, among others. The article includes the diagnostic criteria for IgG-AQP4 positive and negative NMOSD and describes the treatments used in the acute phase and to prevent relapses (namely, oral steroid-sparing drugs, rituximab, tocilizumab, and drugs specifically developed for the disease). Some of the patients with seronegative IgG-AQP4 NMOSD will show positivity for the IgG-MOG (myelin oligodendrocyte glycoprotein) marker, which can also manifest as recurrent optic neuritis, acute disseminated encephalomyelitis, or conus medullaris syndrome, among others. The possibility of recurrences in some cases of persistently seropositive anti-MOG associated disease prompts the chronic use of immunomodulators in a similar way to TENMO, with the particularity of the usefulness of immunoglobulins in children. Finally, the epidemiological, clinical, paraclinical and therapeutic differences between multiple sclerosis, TENMO and anti-MOG disease are described.

Referencias bibliográficas

  • Flanagan EP. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn). 2019;25(3):815-44.
  • Costello F. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn). 2022;28(4):1131-70. 2022;28(6):1859.
  • Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603-5.
  • Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012;69(8):1026-31.
  • Sepúlveda M, Sola Valls N, Escudero D, Rojc B, Barón M, Hernández Echebarría L. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018;24(13):1753-9.
  • Shahmohammadi S, Doosti R, Shahmohammadi A, Azimi A, Sahraian MA, Fattahi MR. Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. Mult Scler Relat Disord. 2021;56:103227.
  • Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.
  • Kim HJ, Paul F, Lana Peixoto MA, Tenembaum S, Asgari N, Palace J. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-73.
  • Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401.
  • Longbrake E. Myelin oligodendrocyte glycoprotein-associated disorders. Continuum (Minneap Minn). 2022;28(4):1171-93.
  • Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218.
  • Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014;261(1):17-26.
  • Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15(1):302.
  • Seneviratne SO, Marriott M, Ramanathan S, Yeh W, Brilot Turville F, Butzkueven H. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurol. 2022;22(1):84.
  • Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34(4):919-39.
  • Alves CS, Santos FBC, Diniz DS. Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil. Arq Neuropsiquiatr. 2022;80(5):497-504.
  • Mireles Ramírez MA, Velázquez Brizuela IE, Sánchez Rosales N, Márquez Pedroza Y, Hernández Preciado MR, Gabriel Ortiz G. The prevalence, incidence, and clinical assessment of neuromyelitis optica spectrum disorder in patients with demyelinating diseases. Neurologia (Engl Ed). 2022;S2173-5808(22)00079-7.
  • Hyun JW, Lee HL, Jeong WK, Lee HJ, Shin JH, Min JH. Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases. Mult Scler. 2021;27(6):964-7.
Fonte de datos: Dialnet